Key facts and Forecast
Results of fiscal 2022
- Group net sales rise 12.9% to € 22.2 billion
- EBITDA pre up 12.2% to € 6.8 billion
- “Big 3” businesses generate almost 90% of organic sales growth
- Dividend proposal: € 2.20 per share
Forecast for fiscal 2023
- Net sales: slight to solid organic growth
- EBITDA pre: organically moderate decline to about stable
- Negative foreign exchange effects expected
Overview: Business performance in fiscal 2022
| Fiscal 2022 | Change (in %, compared to fiscal 2021) | Organic growth (in %, compared to fiscal 2021) |
---|---|---|---|
Group net sales |
22.2 |
12.9 |
6.4 |
EBITDA pre |
6.8 |
12.2 |
6.1 |
Life Science sales |
10.4 |
15.4 |
8.2 |
Healthcare sales |
7.8 |
10.6 |
5.5 |
Electronics sales |
4.0 |
11.3 |
3.7 |




We delivered profitable growth in fiscal 2022 despite challenges.
-
Annual report 2022 (PDF)
Online Report Download (PDF)Detailed information about our business in the fiscal year 2022.
ADDITIONAL INFORMATION
Downloads for the Media
Additional Downloads
- Presentation for Analysts (PDF)
- Financial Statement (XLS)
- Financial Statement (PDF)
- Regional Sector Sales (XLS)
- Summary (PDF)
Annual Reports Archive
Find previous Annual Reports, Corporate Governance Reports & Statements in our archive.
Read more
Conference calls for the media and analysts
- The annual press conference and the conference call for analysts are available as a recording
Related News
View All News-
Press Releases
Fiscal 2022: Merck KGaA, Darmstadt, Germany, Delivers Profitable Growth Despite ...
Merck KGaA, Darmstadt, Germany delivered profitable growth despite challenges in fiscal 2022. Group net sales increased by 12.9% (organically: 6.4%) to € 22,232 million compared with the previous year.
2023/03/02
Share Price
Our interactive Share Price Tool provides you with all the information you need. You can retrace our development within the last ten years or follow it in real time – or compare our share price to various indices.
Check Share Price